NCT00174564已完成2 期
A Multicentre Phase II Trial of Gemcitabine and Oxaliplatin (GEMOX) in Patients With Biliary Tract Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 67
- 主要终点
- To evaluate response rate according to RECIST criteria
研究概览
简要总结
The primary objective is to evaluate the efficacy of the GEMOX treatment as 1st line therapy in patients with advanced biliary tract cancer based on response rate measured by the RECIST unidimensional criteria.
Secondary objectives are : Progression free survival, overall survival and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven, locally advanced or metastatic carcinoma of the biliary tract (gallbladder, intrahepatic bile ducts, extrahepatic bile ducts, ampula of Vater)
- •For intrahepatic bile ducts, if the diagnosis of biliary tract origin is not evident by imaging or surgical exploration, and so equivalent to liver metastasis with unknown primary site, inclusion is possible if:
- •unknown primary after an exhaustive search for the primary site (chest radiography- , thoracic and abdomino pelvic CT scan, colonoscopy, oesogastroduodenal endoscopy, PSA determination for men or mammography for women, and PET scan if possible).
- •histological examination compatible with adenocarcinoma of bile ducts with the immunostaining expression of cytokeratin : 7+, 20- and 19 +. (Shimonishi, 2000 ^22)
- •No prior chemotherapy for advanced disease (first line)
- •No radiation therapy within 4 weeks prior to the first gemcitabine administration.
- •Unidimensionally measurable disease.
- •For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception
- •No known allergy to one of the study drugs
- •No prior malignancy
- •No CNS metastases
- •No peripheral neuropathy > grade 2
- •ECOG PS <=2
- •ANC > 1.5 X 10^9 /L
- •Platelets > 100 X 10^9 /L
- •Creatinine < 1.5 x ULN
- •SGPT (ALT) < 5 x ULN
- •Bilirubin < 2.5 x ULN (patients with jaundice or evidence of bile duct obstruction and in whom the biliary tree can be decompressed by endoscopic percutaneous endoprothesis, with subsequent reduction in bilirubin < 2.5 x ULN will be eligible for the study).
排除标准
- 未提供
结局指标
主要结局
To evaluate response rate according to RECIST criteria
次要结局
- To evaluate the progression-free survival in the ITT population
- To investigate safety using NCI-CTC criteria version 2
研究者
相似试验
已完成
2 期
A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTCAdenocarcinoma of GallbladderCholangiocarcinomaNCT01267344National Health Research Institutes, Taiwan122
Unknown
2 期
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.Diffuse Large B-cell LymphomaNCT01670370The First Affiliated Hospital with Nanjing Medical University60
已完成
2 期
Cetuximab + Gemox in Biliary Tract CancerUnresectableLocally AdvancedMetastaticNCT01216345Association of Research on the Biology of Liver Tumors30
已完成
1 期
Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic CancerAdvanced Pancreatic CancerNCT01048320Royal Marsden NHS Foundation Trust36
已完成
2 期
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerLung CancerNCT00193453SCRI Development Innovations, LLC69